Drug General Information
Drug ID	D06EMM
Former ID	DIB010260
Drug Name	CERC-301
Indication	Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]		Phase 2	[525218]
Company	Cerecor
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Glutamate [NMDA] receptor subunit epsilon 2	Target Info	Antagonist	[533310]
KEGG Pathway	Ras signaling pathway
	Rap1 signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Circadian entrainment
	Long-term potentiation
	Glutamatergic synapse
	Dopaminergic synapse
	Alzheimer's disease
	Amyotrophic lateral sclerosis (ALS)
	Huntington's disease
	Cocaine addiction
	Amphetamine addiction
	Nicotine addiction
	Alcoholism
	Systemic lupus erythematosus
PANTHER Pathway	Huntington disease
	Ionotropic glutamate receptor pathway
	Metabotropic glutamate receptor group III pathway
	Metabotropic glutamate receptor group I pathway
	Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Pathway Interaction Database	ErbB4 signaling events
	Reelin signaling pathway
Reactome	EPHB-mediated forward signaling
	Unblocking of NMDA receptor, glutamate binding and activation
	CREB phosphorylation through the activation of CaMKII
	Ras activation uopn Ca2+ infux through NMDA receptor
	RAF/MAP kinase cascade
WikiPathways	Hypothetical Network for Drug Addiction
	Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
	BDNF signaling pathway
References
Ref 525218	ClinicalTrials.gov (NCT02459236) A Study of Intermittent Doses of CERC-301 in MDD.
Ref 533310	Inhibition of in vivo [3H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Aug 29. pii: S0014-2999(15)30217-X.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.